Pocket Guidelines on Dyslipidaemias

Order Pocket Guidelines

Table of contents

• Development of the Joint Task Force guidelines
• Total cardiovascular risk
  
  • Total cardiovascular risk estimation
  • Risk levels
    • Role of non-invasive cardiovascular imaging techniques on the assessment of total cardiovascular disease risk
    • Risk-based intervention strategies
• Lipids and lipoproteins
  • The biological role of lipids and lipoproteins
• Treatment targets and goals
• Lifestyle modifications to improve the plasma lipid profile
  • Influence of lifestyle on total cholesterol and low-density lipoprotein cholesterol levels
  • Lifestyle recommendations to improve the plasma lipid profile
  • Dietary supplements and functional foods for the treatment of dyslipidaemias
  • Other features of a healthy diet contributing to cardiovascular disease prevention
• Drugs for treatment of dyslipidaemias
  • Statins
  • Cholesterol absorption inhibitors
  • Bile acid sequestrants
  • PCSK9 inhibitors
  • Lomitapide
  • Mipomersen
  • Fibrates
  • n-3 fatty acids
  • Strategies to control plasma cholesterol
• Management of dyslipidaemias in different clinical settings
  • Familial hypercholesterolaemia
  • Women
  • Older people
  • Diabetes and metabolic syndrome
  • Patients with acute coronary syndromes and patients undergoing percutaneous coronary intervention
  • Stroke
  • Heart failure and valvular diseases
  • Chronic kidney disease
  • Transplantation
  • Peripheral arterial disease
  • Other special populations at risk of atherosclerotic cardiovascular disease
• Inflammation
• Monitoring of lipids and enzymes in patients on lipid-lowering therapy
• Cost-effectiveness of cardiovascular disease prevention by lipid modification
• Strategies to encourage the adoption of healthy lifestyle changes and adherence to lipid-modifying therapies